PRESS RELEASE

Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma

- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme
- TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe
- The submission covers countries of the European Union as well as Iceland, Liechtenstein and Norway

Paris, France – 10 March 2022 – Servier, a global pharmaceutical company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for TIBSOVO (ivosidenib tablets) for two indications as a first line treatment, in combination with azacitidine, in patients with previously untreated IDH1-mutated acute myeloid leukemia (AML) and not eligible for intensive chemotherapy, as well as in previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma. TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme. TIBSOVO is the first IDH1 mutation specific targeted therapy to be submitted for registration in Europe.

"This MAA submission is a further step towards the availability of TIBSOVO in Europe, a targeted therapy for patients with previously untreated IDH1-mutated acute myeloid leukemia, and previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma – two rare cancers for which therapeutic options are limited", said Claude Bertrand, Executive Vice President R&D of the Servier Group. *"We look forward to working with the EMA throughout the evaluation process of TIBSOVO, which is the first IDH1 mutation specific targeted therapy to be submitted in Europe."*

AML is a cancer of the blood and bone marrow marked by rapid disease progression. It is the most common acute leukemia in adults and affects 5.06/100,000 inhabitants in Europe, i.e., more than 20,000 new cases each year.[1] The five-year survival rate for people over 60 is 20%.[2]

Cholangiocarcinoma, a cancer of the bile ducts, is a rare and aggressive tumor often linked to medical history such as cirrhosis or liver infection. Cholangiocarcinoma affects 1–3/100,000 inhabitants in Europe, i.e., approximately 10,000 new cases each year in Europe.[3] The five-year survival rate is 9%, but 0% if metastasized.[4] Only surgery can cure patients, but the treatment is only possible for a limited number of patients and the risk of relapse remains high. Chemotherapy is the standard therapy for

[1] ESMO Guidelines 2020 - Acute myeloid leukemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
[2] National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html. Accessed December 7, 2017.)
[3] Valle JW, et al. *Ann Oncol.* 2016;27(Suppl. 5):v28–v37
[4] Oliveira IS, et al. *Abdom Radiol (NY).* 2017;42(6):1637–1649

patients with cholangiocarcinoma who are not eligible for surgery or whose disease has progressed after surgery. The development of immunotherapy and new targeted therapies is now increasing the life expectancy and quality of life of patients.

"At Servier, we are committed to finding new therapeutic solutions for patients with difficult-to-treat cancers with high unmet medical needs. With this filing submission to the EMA, we hope to soon be able to make TIBSOVO available to patients with newly diagnosed IDH1-mutated AML, and to patients suffering from previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma", explained Dr. Philippe Gonnard, Executive Vice President Global Medical & Patient Affairs of the Servier Group.

The submission covers the 27 countries of the European Union as well as Iceland, Liechtenstein and Norway.

TIBSOVO[5] is currently approved in the United States as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory AML and for the treatment of adults with newly diagnosed IDH1-mutant AML who are ≥75 years old, or who have comorbidities that preclude the use of intensive induction chemotherapy. TIBSOVO is also, since 2021, the first and only targeted therapy approved by the U.S. Food and Drug Administration for patients with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma. TIBSOVO is currently approved by the NMPA of China for the treatment of adult patients with relapsed or refractory AML who have a susceptible IDH1 mutation.

Find out more about cholangiocarcinoma and acute myeloid leukemia on servier.com.

About Servier

Servier is a global pharmaceutical Group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent Group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: servier.com

Follow us on social media:

Servier press contact: Sonia Marques: presse@servier.com – Tel. +33 (0)1 55 72 40 21 / +33 (0)7 84 28 76 13

[5] Servier has an exclusive license agreement with CStone for the development and commercialization of TIBSOVO (ivosidenib tablets) in Mainland China, Taiwan, Hong Kong, Macau and Singapore.